Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a contract manufacturing agreement with EDP Biotech, a medical device company focused on the development and commercialization of immunodiagnostic tests for humans. Under terms of the 10-year agreement, Corgenix will manufacture and supply the ColoMarker™ diagnostic test, a blood test developed to detect the early stages of colon cancer. Corgenix recently announced the expansion of its Contract Services business unit and launched a dedicated Contract Services website. “We are pleased to enter into this mutually beneficial relationship with EDP,” said Douglass Simpson, President and CEO of Corgenix. “This reflects our strategic focus on the Contract Services portion of our business for diagnostic products, and it meets the increasing demand overall for contract services in the medical device and biotechnology industries.” ColoMarker is a simple blood test designed to identify potential cases of early stage colon cancer. ColoMarker requires no advance preparation by the patient such as fasting or colon cleansing and can be added easily to the panel of blood tests routinely performed at a patient’s annual physical. About EDP Biotech Corporation EDP Biotech (EDP) is a medical device company focused on the development and sale of human immunodiagnostic tests. EDP utilizes more than 30 years of research and development in the identification and purification of proteins present in the early stages of biological changes for production of in vitro diagnostics test whose primary target is the development of early detection products. For additional information, visit EDP Biotech online at www.edpbiotech.com . About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).